Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000617828 | SCV000737275 | uncertain significance | Cardiovascular phenotype | 2024-06-21 | criteria provided, single submitter | clinical testing | The p.E471K variant (also known as c.1411G>A), located in coding exon 4 of the BAG3 gene, results from a G to A substitution at nucleotide position 1411. The glutamic acid at codon 471 is replaced by lysine, an amino acid with similar properties. This variant was reported in a BAG3 study cohort, and in a dilated cardiomyopathy cohort however, clinical details were limited (Domínguez F et al. J Am Coll Cardiol, 2018 11;72:2471-2481; Boen HM. Cardiooncology. 2024 Apr;10(1):26). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, the clinical significance of this variant remains unclear. |
Labcorp Genetics |
RCV000686010 | SCV000813513 | uncertain significance | Myofibrillar myopathy 6; Dilated cardiomyopathy 1HH | 2024-11-19 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 471 of the BAG3 protein (p.Glu471Lys). This variant is present in population databases (rs778496291, gnomAD 0.006%). This variant has not been reported in the literature in individuals affected with BAG3-related conditions. ClinVar contains an entry for this variant (Variation ID: 519166). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt BAG3 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV000686010 | SCV002796411 | uncertain significance | Myofibrillar myopathy 6; Dilated cardiomyopathy 1HH | 2022-02-15 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003144397 | SCV003829740 | uncertain significance | not provided | 2020-01-23 | criteria provided, single submitter | clinical testing | |
Molecular Diagnostic Laboratory for Inherited Cardiovascular Disease, |
RCV000617828 | SCV006066938 | likely pathogenic | Cardiovascular phenotype | 2022-12-13 | criteria provided, single submitter | clinical testing |